期刊
PHARMACEUTICAL BIOLOGY
卷 61, 期 1, 页码 324-336出版社
TAYLOR & FRANCIS LTD
DOI: 10.1080/13880209.2023.2169468
关键词
Randomized controlled trials; traditional Chinese medicine; effectiveness; adverse event
This study evaluated the efficacy and safety of Tripterygium glycosides (TG) combined with H1-antihistamine (H1-AH) in treating chronic urticaria (CU). The results showed that TG plus H1-AH was more effective in improving cure rate, total efficacy rate, reducing pruritus, wheal number and wheal size, and decreasing serum level of immunoglobulin E (IgE), compared to H1-AH alone. The incidence of adverse events between the two groups was not significantly different.
Context: Tripterygium glycosides (TG), a traditional Chinese medicine, has been used to treat chronic urticaria (CU) in China, and the evidence of TG for CU needs to be updated thoroughly.Objective: To systematically evaluate the efficacy and safety of TG combined with H1-antihistamine (H1-AH) in adults with CU.Methods: Eligible randomized controlled trials were searched in eight databases until May 31, 2022, including CNKI, WanFang, VIP, SinoMed, PubMed, Cochrane Library, Embase, and Web of Science. The search terms included urticaria, Tripterygium, Lei Gong Teng, and Leigongteng. Rev Man 5.3 and Stata 12.0 were used for statistical analysis.Results: A total of 27 studies with 2788 patients were included. The pooled results showed that TG plus H1-AH was superior to H1-AH alone in cure rate (RR = 1.37, 95% CI = 1.15 to 1.63, p = 0.0003), total efficacy rate (RR = 1.40, 95% CI = 1.30 to 1.50, p < 0.00001), pruritus (MD = -0.32, 95% CI = -0.54 to -0.11, p = 0.003), wheal number (MD = -0.31, 95% CI = -0.55 to -0.07, p = 0.01), wheal size (MD = -0.32, 95% CI = -0.46 to -0.19, p < 0.00001), and the serum level of immunoglobulin E (SMD = -1.39, 95% CI = -2.42 to -0.36, p = 0.008). Moreover, adverse events between two groups were mild, and their incidences were not significantly different.Conclusions: The combination of TG and H1-AH is a promising and safe treatment for adults with refractory CU. Further high-quality studies are needed to confirm the evidence.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据